Clinical and Safety Outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Scientists rigorously compared the clinical and safety profiles of the BeEAM and CEM regimens. A controlled, randomized clinical trial was conducted with 58 lymphoma patients undergoing ASCT at the International Medical Center in Cairo, Egypt.